Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Investor Presentation (September 2025)
24 slides from Amplia Therapeutics's investor presentation, Sep 11, 2025
Slide 1: Sydney Investor Briefing
Sydney Investor Briefing 11 September 2025 Chris Burns PhD GAICD FAHMS Rhiannon Jones PhD GAICD ampliatx.com | @ampliatx 1
Slide 2: Disclaimer
DISCLAIMER This presentation (Presentation) contains summary information about Amplia Therapeutics market, regulatory and other relevant environments that will exist and affect Amplia’s business and Limited ACN 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 30 operat
Slide 3: Executive Summary
EXECUTIVE SUMMARY Developing a pipeline of small molecule inhibitors of FAK Lead drug narmafotinib is best-in-class FAK inhibitor in development Promising efficacy, durability and tolerability in Phase 2a ACCENT clinical trial in pancreatic cancer New trial of narmafotinib in pancreatic cancer now u
Slide 4: Company Summary
COMPANY SUMMARY ASX: ATX ATX Price and Volume - 12 months Share price $0.188 (26 Aug 2025) Share price range $0.049 - 0.42 (52 week low/high) Shares on issue 486.48M Market capitalization $91.2M (approx.) (26 Aug 2025) 4
Slide 5: Board + Management
BOARD + MANAGEMENT World-class experts BOARD SENIOR MANAGEMENT Rhiannon Jones PhD GAICD COO Warwick Tong Robert Peach Jane Bell Chris Burns* MB ChB MPP GAICD PhD LLB LLM (Lond) FAICD PhD GAICD Director CEO and MD Jason Lickliter Chair Director MBBS FRACP CMO Tim Luscombe BCom CA GIA(Cert) CFO * Co-R
Slide 6: Metastatic Pancreatic Cancer
METASTATIC PANCREATIC CANCER Limited treatment options; poor patient outcomes 5Y Survival Limited Treatment Options Median Progression Median Overall Treatment Tolerability Free Survival Survival Gemcitabine + Abraxane ® 5.5 months 8.5 months 3% (MPACT study) FOLFIRINOX 6.4 months 11.1 months (Prodi
Slide 7: Metastatic Pancreatic Cancer: Can narmafotinib improve response to chemotherapy?
METASTATIC PANCREATIC CANCER Limited treatment options; poor patient outcomes Can narmafotinib improve response to chemotherapy? What about new treatments in development? 7
Slide 8: Narmafotinib: A Potent and Selective FAK Inhibitor
NARMAFOTINIB: A POTENT AND SELECTIVE FAK INHIBITOR An Australian Discovery Drug discovered at Cooperative Research Centre for Cancer Therapeutics Government supported industry - academic partnership Focus on potential in treatment of solid cancers Excellent preclinical profile Drug-like properties P
Slide 9: Narmafotinib: A Potent and Selective FAK Inhibitor
NARMAFOTINIB: A POTENT AND SELECTIVE FAK INHIBITOR FAK enzyme overactive in pancreatic cancer Benefits of FAK Inhibition Anti-proliferative Synergy with FAK levels are elevated in pancreatic cancer Reduces cells’ ability chemotherapies Correlate with worse patient outcome to proliferate Enhances act
Slide 10: Narmafotinib: A Potent and Selective FAK Inhibitor
NARMAFOTINIB: A POTENT AND SELECTIVE FAK INHIBITOR FAK enzyme overactive in pancreatic cancer Benefits of FAK Inhibition Anti-proliferative Synergy with FAK levels are elevated in pancreatic cancer Reduces cells’ ability chemotherapies Correlate with worse patient outcome to proliferate Enhances act
Slide 11: The Amplia Advantage
THE AMPLIA ADVANTAGE Three critical features Efficacy Narmafotinib Tolerability Durability 11
Slide 12: ACCENT Trial in Pancreatic Cancer
ACCENT TRIAL IN PANCREATIC CANCER Phase 1b/2a study in Australia and Korea Intermittent dosing schedule OBJECTIVE narmafotinib To determine safety and efficacy of narmafotinib Gemcitabine + when added to standard of care Abraxane in newly diagnosed patients PRIMARY ENDPOINTS Safety, Tolerability ORR
Slide 13: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Median Progression Free Survival (mPFS) data All ACCENT patients @ 400 mg (n = 64) Currently determined at 7.6 months - substantially better than chemotherapy alone (5.5 months) Interim data with 17 patients still
Slide 14: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability ACCENT Trial MPACT Trial Excellent response rate observed (Narmafotinib/Gemcitabine/ (Gemcitabine/ 1 confirmed Complete Response Abraxane) Abraxane) 16 confirmed Partial Responses CR 2% 0.2% Incl. 1 patient determi
Slide 15: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability ACCENT Trial MPACT Trial Excellent response rate observed (Narmafotinib/Gemcitabine/ (Gemcitabine/ 1 confirmed Complete Response Abraxane) Abraxane) 16 confirmed Partial Responses CR 2% 0.2% Incl. 1 patient determi
Slide 16: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability ACCENT Trial MPACT Trial Excellent response rate observed (Narmafotinib/Gemcitabine/ (Gemcitabine/ 1 confirmed Complete Response Abraxane) Abraxane) 16 confirmed Partial Responses CR 2% 0.2% Incl. 1 patient determi
Slide 17: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability ACCENT Trial MPACT Trial Excellent response rate observed (Narmafotinib/Gemcitabine/ (Gemcitabine/ 1 confirmed Complete Response Abraxane) Abraxane) 16 confirmed Partial Responses CR 2% 0.2% Incl. 1 patient determi
Slide 18: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Excellent tolerability observed to date Narmafotinib treatment results in negligible extra patient burden Adverse Events (Grade 3 or above) Narmafotinib + Gem/Abr (ACCENT; N=55) Gem/Abr (MPACT; N=421) 40 30 20 10 0
Slide 19: ACCENT Trial Summary
ACCENT TRIAL SUMMARY On track to achieve trial goals Superior Efficacy Improved Durability Demonstrated Tolerability For full 55 patient cohort 7 patients on trial for >12 Excellent tolerability profile 1 CR months 16 PR (incl. 1 pCR) Minimal additional burden on Deep and sustained response the pati
Slide 20: AMPLICITY Trial in mPDAC
AMPLICITY TRIAL in mPDAC Phase 1b/2a study in the US and Australia Moving from intermittent to daily dosing OBJECTIVE To determine safety and efficacy of narmafotinib narmafotinib when added to FOLFIRINOX in newly diagnosed patients FOLFIRINOX To identify recommended phase 2 dose (RP2D) PRIMARY ENDP
Slide 21: AMPLICITY Trial
AMPLICITY TRIAL Phase 1b/2a study in Pancreatic Cancer in the US and Australia Objective To determine safety and efficacy of narmafotinib when added to FOLFIRINOX in newly diagnosed metastatic patients To identify recommended phase 2 dose (RP2D) Entry from clinicaltrials.gov/study/NCT07026279 Primar
Slide 22: Future Opportunities
FUTURE OPPORTUNITIES FAK inhibition will enhance multiple therapeutic strategies Narmafotinib (FAK inhibition) CHEMOTHERAPY IMMUNOTHERAPIES Clinical and preclinical data incl. Preclinical data ACCENT study KRAS INHIBITORS RADIOTHERAPY Preclinical data, incl. Published data collaboration ANTIBODY DRU
Slide 23: Upcoming Milestones
UPCOMING MILESTONES Q3 2025 Q4 2025 Q1 2026 Q2 2026 2H 2026 ACCENT top-line data ACCENT further patient ACCENT mature data ACCENT trial completion ACCENT full data release updates (including OS) possible ACCENT request FDA type AMPLICITY 2-dose comparison trial C meeting - Phase 2b/3 AMPLICITY first
Slide 24: Thank You
THANK YOU Chris Burns PhD GAICD FAHMS [email protected] Rhiannon Jones PhD GAICD [email protected] Amplia Therapeutics Limited ASX: ATX [email protected] ampliatx.com 24
Amplia Therapeutics — Investor Presentation (September 2025) on 6ix